Switch theme
Sign up to access all valuation multiples
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.
2008
61
LTM Revenue $6.3M
LTM EBITDA -$16.5M
$154M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Scancell has a last 12-month revenue (LTM) of $6.3M and a last 12-month EBITDA of -$16.5M.
In the most recent fiscal year, Scancell achieved revenue of n/a and an EBITDA of -$9.6M.
Scancell expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Scancell valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.3M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $5.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 93% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$16.5M | XXX | -$9.6M | XXX | XXX | XXX |
| EBITDA Margin | -261% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$17.8M | XXX | -$24.9M | XXX | XXX | XXX |
| EBIT Margin | -282% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$15.4M | XXX | -$8.0M | XXX | XXX | XXX |
| Net Margin | -243% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $5.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Scancell's stock price is GBP 0 (or $0).
Scancell has current market cap of GBP 106M (or $145M), and EV of GBP 113M (or $154M).
See Scancell trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $154M | $145M | XXX | XXX | XXX | XXX | $-0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Scancell has market cap of $145M and EV of $154M.
Scancell's trades at n/a EV/Revenue multiple, and -10.7x EV/EBITDA.
Equity research analysts estimate Scancell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Scancell has a P/E ratio of -9.4x.
See valuation multiples for Scancell and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $145M | XXX | $145M | XXX | XXX | XXX |
| EV (current) | $154M | XXX | $154M | XXX | XXX | XXX |
| EV/Revenue | 24.3x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -9.3x | XXX | -10.7x | XXX | XXX | XXX |
| EV/EBIT | -8.6x | XXX | -7.6x | XXX | XXX | XXX |
| EV/Gross Profit | 26.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -9.4x | XXX | -11.0x | XXX | XXX | XXX |
| EV/FCF | -9.9x | XXX | -9.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialScancell's last 12 month revenue growth is -86%
Scancell's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.4M for the same period.
Scancell's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Scancell's rule of X is -476% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Scancell and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -86% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -261% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -476% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Scancell acquired XXX companies to date.
Last acquisition by Scancell was XXXXXXXX, XXXXX XXXXX XXXXXX . Scancell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Scancell founded? | Scancell was founded in 2008. |
| Where is Scancell headquartered? | Scancell is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Scancell have? | As of today, Scancell has 61 employees. |
| Who is the CEO of Scancell? | Scancell's CEO is Dr. Philip John L'Huillier. |
| Is Scancell publicy listed? | Yes, Scancell is a public company listed on LON. |
| What is the stock symbol of Scancell? | Scancell trades under SCLP ticker. |
| When did Scancell go public? | Scancell went public in 2010. |
| Who are competitors of Scancell? | Similar companies to Scancell include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Scancell? | Scancell's current market cap is $145M |
| What is the current revenue of Scancell? | Scancell's last 12 months revenue is $6.3M. |
| What is the current revenue growth of Scancell? | Scancell revenue growth (NTM/LTM) is -86%. |
| What is the current EV/Revenue multiple of Scancell? | Current revenue multiple of Scancell is 24.3x. |
| Is Scancell profitable? | Yes, Scancell is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Scancell? | Scancell's last 12 months EBITDA is -$16.5M. |
| What is Scancell's EBITDA margin? | Scancell's last 12 months EBITDA margin is -261%. |
| What is the current EV/EBITDA multiple of Scancell? | Current EBITDA multiple of Scancell is -9.3x. |
| What is the current FCF of Scancell? | Scancell's last 12 months FCF is -$15.6M. |
| What is Scancell's FCF margin? | Scancell's last 12 months FCF margin is -246%. |
| What is the current EV/FCF multiple of Scancell? | Current FCF multiple of Scancell is -9.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
